

IISPV Postdoctoral Fellowship Program

| | |
|-------------------------|--|
| APPLICANT | |
| CONSOLIDATED GROUP HOST | |
| PROJECT | |

a) RESEARCH GROUP **10%** *Evaluation made by the IISPV Technical Office*

| Nº | Reference | Points | Type | |
|----|-----------|-------------|---|--|
| | Table 1 | | Competitive International Projects (Period 2009-2013) | N: Number of projects shown in Table 1 |
| | Table 2 | | Non-Competitive Projects (Period 2009-2013) | N: Number of projects shown in Table 2 |
| | Table 2 | | Clinical Trials (Period 2009-2013) | N: Number of clinical trials shown in Table 2 |
| | Table 3 | | €/Project. Competitive Projects (Period 2009-2013) | €/ N project / period shown in Table 3 |
| | Table 4 | | €/Project. Non-Competitive Projects (Period 2009-2013) | €/ N project / period shown in Table 4 |
| | Table 4 | | €/Project. Clinical trials (Period 2009-2013) | €/ N project / period shown in Table 4 |
| | Table 2 | | International scope of host group (Period 2009-2013) | N: number of international links: international research groups in competitive projects |
| | Table 1 | | Post-Doc (Period 2009-2013) | N: number of Post-Doc work contracts shown in Table 1 |
| | Table 5 | | Participation in national research networks | CIBER/Retic/Other |
| | Table 5 | | Participation in international research networks | |
| | Table 1 | | Attracting international researchers | N: number of international researchers - Mobility to Group > 6 months – Period 2010-2013 |
| | Table 1 | | R&D&I Projects (2010-2013) | N: number of projects shown in Table 1 |
| | Table 2 | | Pluridisciplinary: teams & group members | N: health care, basic sciences & clinical practice Groups |
| | Table 1 | | Collaboration with other members of IISPV | N: number of collaborations shown in Table 1 |
| | Table 5 | | Internationalisation & promotion of research | YES / No |
| | Table 6 | | Number of indexed publications (first and second quartile, Period 2010-2013) | |
| | Table 7 | | Total Impact Factor (Period 2010-2013) | |
| | Table 7 | | H Index (Director) | Consultative source: the Web of Science / the Web of Knowledge |
| | Table 1 | | Clinical guides or other biomedical documents (prevention, diagnostic, prognostic, therapy, etc) (Period 2010-2013) | N: number of biochemical application documents shown in Table 1 |
| | Table 1 | | Patents and Usage Models | N: name of intellectual property shown in Table 1 |
| | | 0,00 | | |

| | | |
|---------------|-------------|--------|
| Maximum value | 26,50 | Points |
| Group value | 0,00 | Points |

weighted around 1 (10%, 1 Point)

| Table 1 | N | |
|---------|------|------|
| | 1 | 1,40 |
| | 2 | 1,55 |
| | 3 | 1,70 |
| | 4 | 1,85 |
| 5 o >5 | 2,00 | |

| Table 2 | N | |
|---------|------|------|
| | 0 | 0,00 |
| | 1 | 0,20 |
| | 2 | 0,40 |
| | 3 | 0,60 |
| | 4 | 0,80 |
| 5 o >5 | 1,00 | |

| Table 3 | euros/project | |
|---------|---------------|------|
| | 0 | 0,00 |
| | 0.1- 1000 | 1,25 |
| | 1000 -3000 | 1,50 |
| | 3001- 7000 | 1,75 |
| > 7000 | 2,00 | |

| Table 4 | euros/project | |
|---------|---------------|------|
| | 0 | 0,00 |
| | 0.1- 1000 | 0,25 |
| | 1000 -3000 | 0,50 |
| | 3001- 7000 | 0,75 |
| > 7000 | 1,00 | |

| Table 5 | N | |
|---------|-----|-----|
| | Yes | 0,5 |
| No | 0,0 | |

| Table 6 | N | |
|----------|---------|------|
| | 1 a 5 | 0,20 |
| | 5 a 10 | 0,40 |
| | 10 a 20 | 0,60 |
| | 20 a 35 | 0,80 |
| 35 o >35 | 1,00 | |

IISPV Postdoctoral Fellowship Program

| | |
|-------------------------|--|
| APPLICANT | |
| CONSOLIDATED GROUP HOST | |
| PROJECT | |

b) PROJECT (50%, 5 Points) *External evaluator*

| PROJECT ASSESSMENT | Evidence |
|---|---|
| The proposal objectives and the hypothesis are suitable | 3: Strongly agree // 2: Agree // 0.5: Disagree // 0: Totally disagree |
| The clinical or biomedical environment is appropriate | 3: Strongly agree // 2: Agree // 0.5: Disagree // 0: Totally disagree |
| Taking into account the proposal objectives, the study design is suitable | 3: Strongly agree // 2: Agree // 0.5: Disagree // 0: Totally disagree |
| The investigators (Group and applicant) are sufficiently familiar with the study area | 3: Strongly agree // 2: Agree // 0.5: Disagree // 0: Totally disagree |
| The proposal is original and/or innovative | 3: Strongly agree // 2: Agree // 0.5: Disagree // 0: Totally disagree |
| The proposal, in comparison with other current research projects, is relevant | 3: Strongly agree // 2: Agree // 0.5: Disagree // 0: Totally disagree |
| The methods-materials-techniques of the proposed study and the timing are correct | 3: Strongly agree // 2: Agree // 0.5: Disagree // 0: Totally disagree |
| It adds value to the research group | 3: Strongly agree // 2: Agree // 0.5: Disagree // 0: Totally disagree |
| It adds value to the Catalan/Spanish or European System of Scientific Investigation | 3: Strongly agree // 2: Agree // 0.5: Disagree // 0: Totally disagree |
| It adds impact to the innovation and transfer of technology in economic growth | 3: Strongly agree // 2: Agree // 0.5: Disagree // 0: Totally disagree |
| It adds impact to the innovation and transfer of technology in biomedical investigation | 3: Strongly agree // 2: Agree // 0.5: Disagree // 0: Totally disagree |
| The results and impact on health are expected | 3: Strongly agree // 2: Agree // 0.5: Disagree // 0: Totally disagree |
| The plans for broadcast and information about the project are suitable | 3: Strongly agree // 2: Agree // 0.5: Disagree // 0: Totally disagree |
| The impact of the attention centred on the patient in the results is adequate | 3: Strongly agree // 2: Agree // 0.5: Disagree // 0: Totally disagree |
| There are potential applications and connections with the health care organisations and hospitals | 3: Strongly agree // 2: Agree // 0.5: Disagree // 0: Totally disagree |
| There will be future collaborations and the creation of international networks | 3: Strongly agree // 2: Agree // 0.5: Disagree // 0: Totally disagree |
| The project is novel and the work is expected to be important to clinical application | 3: Strongly agree // 2: Agree // 0.5: Disagree // 0: Totally disagree |
| It benefits the host centre and IISPV | 3: Strongly agree // 2: Agree // 0.5: Disagree // 0: Totally disagree |
| It gives disease prevalence, incidence and preventive therapy | 3: Strongly agree // 2: Agree // 0.5: Disagree // 0: Totally disagree |
| It intervenes in the evaluation of the economic cost of diseases | 3: Strongly agree // 2: Agree // 0.5: Disagree // 0: Totally disagree |
| It results in guides, new clinical protocols and/or better clinical practice | 3: Strongly agree // 2: Agree // 0.5: Disagree // 0: Totally disagree |
| It results in new diagnoses, management and/or treatments | 3: Strongly agree // 2: Agree // 0.5: Disagree // 0: Totally disagree |
| It results in a doctoral thesis for a pre-doctoral student or resident | 3: Strongly agree // 2: Agree // 0.5: Disagree // 0: Totally disagree |
| It results in 2 or more journal publications in the first or second quartile | 3: Strongly agree // 2: Agree // 0.5: Disagree // 0: Totally disagree |
| It results in a new international project | 3: Strongly agree // 2: Agree // 0.5: Disagree // 0: Totally disagree |
| 0 | |

| | | |
|---------------|-------------|--------|
| Maximum value | 75 | Points |
| Score | 0,00 | Points |

weighted around 5 (50%, 5 Points)

c) CANDIDATE *40% External evaluator*

| APPLICANT ASSESSMENT | Evidence |
|--|--|
| Candidate's academic excellence | 3: Strongly agree // 2: Agree // 0.5: Disagree // 0: Totally disagree |
| Publications: TIF investigator is sufficiently familiar with the study area | 3: Strongly agree // 2: Agree // 0.5: Disagree // 0: Totally disagree |
| H Index | Table 6 |
| Qualifications and honours are suitable | 3: Strongly agree // 2: Agree // 0.5: Disagree // 0: Totally disagree |
| Financing of the project: APPLICANT => principal Investigator. TIF candidate has the acquired abilities, competence, and knowledge through a combination of practical and supervised academic experience | 3: Strongly agree // 2: Agree // 0.5: Disagree // 0: Totally disagree |
| Supporting letters: TIF investigator is sufficiently familiar with the field of research and demonstrates great experience in clinical practice | 3: Strongly agree // 2: Agree // 0.5: Disagree // 0: Totally disagree |
| International mobility: High mobility value: a minimum of 1 semestre abroad dedicated to the field of work, academic studies, research and / or conferences and / or a further minimum of 1 semestre abroad during his/her post-doctoral studies | 1: YES // 0: NO |
| Has the ability to communicate the results of the investigation, not only to the scientific community but also to the general population | 3: Strongly agree // 2: Agree // 0.5: Disagree // 0: Totally disagree |
| Has a promising research itinerary | 1: YES // 0: NO |
| Has international experience | 1: YES // 0: NO --> International networking |
| Has scientific merit and a research career | 1: YES // 0: NO |
| Has relevance in the research topic | 1: YES // 0: NO --> PROJECT internacional d'investigacio, PROJECTS competius i no repetitius |
| Has relevant previous publications | 1: YES // 0: NO -> total dels factors d'impacte> 15; Publicacions primer i segon quartil |
| 0 | |

| | | |
|---------------|-------------|--------|
| maximum value | 25 | Points |
| Score | 0,00 | Points |

weighted around 4 (40%, 4 Points)

IISPV Postdoctoral Fellowship Program

| | |
|-------------------------|--|
| APPLICANT | |
| CONSOLIDATED GROUP HOST | |
| PROJECT | |

| | |
|------------------------------|------|
| A) GROUP (10%, 1 Points) | 0,00 |
| B) PROJECT (50%, 5 Points) | 0,00 |
| c) APPLICANT (40%, 4 Points) | 0,00 |

| | | |
|-------------------------|-------|------|
| FINAL SCORE (0 - 10) | A+B+C | 0,00 |
|-------------------------|-------|------|